Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-1RAP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-1RAP ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-1RAP Products |
| Gene Delivery | IL-1RAP Lentivirus Particles Full-length ORF for stable cell line construction. Ideal for internalization and binding assays. |
View IL-1RAP Products |
| Benchmark Ab | Anti-IL-1RAP (Sequence of Nadunolimab/CAN04) Recombinant positive control. High affinity reference for assay development. |
View IL-1RAP Products |
| Validator | IL-1RAP siRNA Set For knockdown verification and specificity confirmation. |
View IL-1RAP Products |
| Related Target: IL-1R1 | IL-1R1 (IL-1 Receptor 1) Primary signaling receptor partner. Required for functional IL-1 signaling assays. |
View IL-1R1 Products |
| Related Target: IL-33 | IL-33 (Cytokine) Shares IL-1RAP as co-receptor component. Critical for counter-screening and pathway selectivity. |
View IL-33 Products |
| Related Target: ST2 | ST2 (IL-1RL1) IL-33 specific receptor chain. Essential for specificity panels to exclude IL-33 pathway interference. |
View ST2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno IL-1RAP ortholog proteins available with >95% purity, Sequence Verified. |
| Subfamily counter screening (IL-1R1/ST2 competition) | Homolog panel proteins (IL-1R1, IL-33, ST2) strictly verified by mass spec for selectivity assays. |
| Internalization efficiency (ADC development) | High-purity ECD-Fc with native conformation. Lentivirus particles for stable overexpression cell lines. |
| Lack of Controls | Clinical Benchmark Antibodies (Nadunolimab biosimilar sequences) included as positive controls. |
| False Positives | Validated siRNA included for target-specificity checks in binding assays. |
Live IL-1RAP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-1RAP therapeutics is intensifying, with major players exploring its dual role in oncology (AML, CML, Solid Tumors) and auto-immune inflammation. As first-generation naked mAbs reach advanced clinical trials, the next wave of R&D is aggressively targeting ADCs and CAR-T cell therapies to leverage IL-1RAP's high surface expression on leukemic stem cells and tumor-associated inflammatory cells. Additionally, combination strategies with IL-1 pathway inhibitors are being explored to overcome immune suppression in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Cantargia AB (CAN04), AstraZeneca, Emerging startups | AML, MDS, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc for binding validation) |
| Monoclonal Antibody | Cantargia AB (Nadunolimab), Novartis | NSCLC, Pancreatic Cancer, Inflammation | Receptor blockade assay (Need high-purity ECD-Fc for ligand competition) |
| Bispecific | Emerging biotech, Early discovery | Hematological Malignancies, Immuno-Oncology | Heterodimer validation (Need cross-reactive Abs and dual-target binding) |
| CAR-T/NK Cell | Academic institutions, Startups | AML (relapsed/refractory), CML | Cell surface expression validation (Need Lentivirus for stable cell lines) |